11/9/2023 0 Comments Kite pharma gilead good for kiteAdditionally, Gilead looks well-positioned to benefit a great deal from its partnership with Arcelix. The treatment is likely to be approved for use in many new indications. Yescarta’s sales are likely to continue to jump going forward. Very encouragingly, “78% of patients saw their tumors shrink or disappear due to the treatment, and 67% of patients showed a complete response, in which their tumors disappeared. In December, Yescarta was given to nine patients with blood cancers in their brain or spinal cords. In the second quarter, Yescarta’s sales jumped 29% versus the same period a year earlier to $380 million. Yescarrta was approved as a treatment for large B-cell lymphoma last year. This combats the 12% expected with standard of care, Gilead reported.Īnd in a Phase 3 trial earlier this year, Yescarta became “the first treatment in nearly 30 years to improve overall survival (OS) in relapsed/refractory large B-cell lymphoma,” BioSpace reported. Among the 62 patients who received Yescarta, 71% showed no signs of disease after three months. The company’s Yescarta therapy recently showed strong efficacy as a treatment for a type of blood cancer called large B-cell lymphoma. Gilead’s GILD Kite unit specializes in developing CAR T therapies. I view it as one of the best cancer drug stocks. I believe that Arcelix can become a pharmaceutical powerhouse. Furthermore, Arcelix is eligible to receive more money from Gilead if CART-ddBCMA is successful down the road. Under the deal, Arcelix received $225 million of cash from Gilead, while GILD bought $100 million of ACLX stock. Gilead GILD in December entered into a partnership with Arcelix two months after the strong data on CART-ddBCMA was unveiled. Further, 71% of the patients showed no signs of cancer after the study was complete. In a Phase 1 study of CART-ddBCMA, the condition of all 38 patients who received the treatment improved. It is a potential treatment for patients with certain kinds of a prevalent blood cancer known as multiple myeloma. Consequently, I view BMY as one of the best cancer drug stocks.Īrcelix ACLX developed a CAR T based treatment called CART-ddBCMA. I believe that the drug can ultimately become a huge blockbuster, significantly lifting Bristol-Myer’s financial results and BMY stock in the process. Last year, the Food and Drug Administration approved Breyzani as a treatment for “adult patients with large B-cell lymphoma.” This is another type of blood cancer.Īlso noteworthy is that BMY is testing the drug’s efficacy in many types of blood cancer. Still, given the fact that the patients had unsuccessfully tried so many other treatments in the past, I believe that the data was impressive. This wasn’t considered statistically significant. On a negative note, the overall response rate of the patients in the study, which represents the proportion of the participants whose condition improved, came in at 42.9%. Also worth noting is that the patients in the study had unsuccessfully tried many other drugs. ” None of the patients in the latter group “experienced disease progression or deaths by the data cutoff,” enabling the treatment to attain the study’s primary endpoint. “In the Phase 1/2 trial “Breyanzi eradicated signs of cancer in 18.4% of patients with heavily pretreated CLL or small lymphocytic lymphoma (SLL). According to Fierce Pharma, CLL is ” the most common form of leukemia. ![]() The therapy, Breyanzi, is a treatment for chronic lymphocytic leukemia (CLL). In January, Bristol Myers-Squibb BMY reported extremely positive data for one of its CAR T therapies. Here are three of the best cancer drug stocks that can advance tremendously, thanks in large part to the CAR T drugs that they’re developing. Finally, “After a one-time infusion, the CAR T cells can continue to multiply in the patient’s body after being administered,” Bristol-Myers Squibb BMY explained. ![]() In other words, CAR T produces treatments that are “personalized” to each patient. Moreover, unlike other cancer treatments, CAR T drugs enlist cells that come from the patients themselves in the cancer-fighting effort. This revolutionary techology has brought up some of the best cancer drug stocks we have ever seen. That’s because the treatments are specifically tailored to each patients’ T cells. One reason this type of therapy is so promising is that it produces treatments that work well within each patients’ body. CAR T also attacks other cells altered by tumors. Specifically, CAR T treatments work by reconfiguring T cells so that they attack proteins found on tumors. CAR T involves “reprogramming” patients’ T cells, which fight hostile cells within the body. ![]() Autologous chimeric antigen receptor T cell therapy is 0ne of the most promising, relatively new types of cancer treatments.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |